Pharming Group N.V. (PHAR) Financials

PHAR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 489.4 million 220.4 million
Dec. 31, 2025 499.8 million 222.8 million
Sept. 30, 2025 403.6 million 178.1 million
June 30, 2025 446.3 million 206.7 million

PHAR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 1.4 million ?
Dec. 31, 2025 7.1 million 4.5 million
Sept. 30, 2025 29.9 million 3.2 million
June 30, 2025 11.6 million 3.5 million

PHAR Net Income

No data available :(

PHAR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 170.9 million 93.4 million 14.7 million
Dec. 31, 2025 179.8 million 92.7 million 17.7 million
Sept. 30, 2025 141.5 million 79.3 million 27.7 million
June 30, 2025 128.7 million 91.3 million 32.0 million

PHAR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 70.1 million
Dec. 31, 2025 75.8 million
Sept. 30, 2025 66.9 million
June 30, 2025 66.9 million

PHAR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 238862 25.6 million 37.9 million 36.7 million
Dec. 31, 2025 269263 32.1 billion 51.3 billion 31.3 billion
Sept. 30, 2025 68693 23.4 million 51.1 million 34.1 million
June 30, 2025 128000 23.7 million 51.6 million 31.0 million

PHAR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 72.7 million 6.7 million
Dec. 31, 2025 106.5 billion 21.1 billion
Sept. 30, 2025 97.3 million 7.1 million
June 30, 2025 93.2 million 9.0 million

PHAR

Price: $13.12

52 week price:
9.54
21.34

Earnings Per Share: 0.19 USD

P/E Ratio: 68.85

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: Netherlands

Volume: 1500

Market Capitalization: 972.5 million

Links: